pancreatic biliary cancer by dr mahipal reddy
TRANSCRIPT
![Page 1: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/1.jpg)
DR MAHIPAL REDDYINDUR ENDOSCOPY CENTRE
NIZAMBAD INDIA
![Page 2: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/2.jpg)
![Page 3: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/3.jpg)
Pathology Exocrine
Solid Infiltrating ductal adenocarcioma: most Variant of ductal adenocarcinoma
Signet-ring cell, medullary, adenosquamous, anaplastic
Acinar cell carcinoma Pancreatoblastoma
Cystic Endocrine
![Page 4: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/4.jpg)
Pathology Exocrine
SolidCystic
Mucinous cystic neoplasm Intraductal papillary mucinous neoplasm Serous cystic neoplasm Solid pseudopapillary neoplasm
Endocrine
![Page 5: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/5.jpg)
Immunohistochemistry Infiltrating ductal adenocarcinoma
Cytokeratin(CK): 7(+), 19(+), 20(-)CEACA19-9Mucins
![Page 6: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/6.jpg)
Risk factors of pancreatic cancerAdvanced ageLow socioeconomic statusCigarette Diabetes mellitusChronic pancreatitisHigh-fat and cholesterol dietCarcinogens exposure
PCBs, DDT, NNK, benzidine
![Page 7: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/7.jpg)
Clinical presentationAbdominal painJaundice, obstructive
Right-side dominantWeight loss, anorexiaNew-onset DMAcute pancreatitis
Especially no risk factors, stones or alcohols
![Page 8: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/8.jpg)
Clinical presentationPhysical signs
Jaundice: skin and scleraHepatomegalyPalpable gall bladderLymphadenopathy
Left supraclavicle: Virchow’s node Periumbilical: Sister Mary Joseph’s node Peri-rectal region: Blumer’s shelf
![Page 9: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/9.jpg)
Diagnosis Image studies
CT or MRI: image of choice, equivalent ERCP: direct imaging of p-duct, replaced by
CT/MRIEUS: more accurate for tumor itself
EUS-FNAPET: to be investigated
Histopathologic diagnosis
![Page 10: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/10.jpg)
Diagnosis Image studiesHistopathologic diagnosis
Direct operation: curative or palliative Percutaneous
More complication: hemorrhage, pancreatitis, fistula, abscess, tract seeding
EUS-FNA
![Page 11: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/11.jpg)
Staging T
T1: limited to pancreas, <2cmT2: limited to pancreas, >2cmT3: extend beyond pancreas, not involve celiac
axis or SMAT4: involve celiac axis or SMA(unresectable)
NN1: regional LN(+)
![Page 12: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/12.jpg)
StagingIA: T1N0M0IB: T2N0M0IIA: T3N0M0IIB: T1N1M0, T2N1M0, T3N1M0III: T4, any N, M0IV: M1
![Page 13: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/13.jpg)
Treatment – surgical resectionPancreatic head and neck
Pancreaticoduodenectomy +/- distal gastrectomy: Whipple’s operation Mortality: 2-3%
Sepsis, hemorrhage , CV event Morbidity: 40-50%
Leakage, abscess, delayed gastric emptying, hemorrhage
Pancreatic tail
![Page 14: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/14.jpg)
Treatment – surgical resectionPancreatic head and neckPancreatic tail
No obstructive jaundice in early state Tend to be larger, usually metastasis at dx
Distal pancreatectomy
![Page 15: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/15.jpg)
Right-side (N=564)
Left-side (N=52)
P value
Tumor diameter
3.1cm 4.7cm <0.01
Margin(+) 30% 20% NS
LN(+) 73% 59% 0.03
Post-op mortality
2.3% 1.9% NS
Overall complication
31% 25% NS
Post-op hospital stay
11d 7d NS
Median survival
18m 12m NS
Right-side versus Left-side pancreatic resection: John Hopkins Experience (1984-1999)
![Page 16: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/16.jpg)
For recurrenceDisease nature
Locally recurrence and distant metsNeoadjuvant/adjuvant treatment
Chemoradiation 5FU, MMC, Cisplatin, Paclitaxel, Gemcitabine Relative radioresistant
Mostly single armNo definite evidence of survival benefit
![Page 17: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/17.jpg)
Unresectable diseasePalliative surgeryRT or CCRT
Radio-resistance 5FU, GemcitabineReally benefit?
Palliative chemotherapy
![Page 18: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/18.jpg)
Palliative surgeryObstructive jaundiceDuodenal obstruction
HepaticojejunostomyCholedochoduodenostomy Cholecystojejunostomy
Pain reliefNeurolysis
![Page 19: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/19.jpg)
Systemic chemotherapy Problems
Highly resistant to chemotherapyUsually poor performance
Pain, N/V, cachexia, weaknessImpaired liver functionUsually lack of measurable lesions
Variation in phase II studies
![Page 20: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/20.jpg)
Chemotherapy – historical 5-FU is cornerstone
Combination with Adramycin, mitomycin: FAM Cyc, MTX, Vincristine, Mitomycin Epirubicin, cisplatin, carboplatin, Ara-C High response rate in phase II : 40% Not confirmed in phase III
Combination not better than 5FU alone
![Page 21: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/21.jpg)
Gemcitabine Well-tolerated agentPhase III study, Gemzar vs. 5-FU
Response rate: 5.4% vs. 0%Survival: 5.65m vs. 4.41m (p=0.0025)Clinical benefit: 23.8% vs. 4.8
Pain, performance status, weight gainToxicity similar with 5-FU
Gemcitabine superior to 5-FU
![Page 22: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/22.jpg)
Gemcitabine-based combination
![Page 23: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/23.jpg)
Gemzar+Tarceva vs. Gemzar
ASCO annual meeting 2005, abstr no. 1
![Page 24: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/24.jpg)
![Page 25: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/25.jpg)
![Page 26: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/26.jpg)
![Page 27: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/27.jpg)
Classification Cholangiocarcinoma
All tumors arise from bile duct epithelium Mostly adenocarcinoma
Intrahepatic (6%)Hilum (67%): Klaskin’s tumorDistal extrahepatic (27%)Gall bladder
![Page 28: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/28.jpg)
Epidemiology Old age: median 65 year-oldSlightly more in menUncommon cancerUncertain nature course and treatment
![Page 29: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/29.jpg)
Risk factorsChronic inflammation
Primary sclerosing cholangitis : autoimmuneCholedochal cyst : congenitalParasite Stone : maybe Repeat inflammation, strictureYoung age-onset
Carcinogens
![Page 30: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/30.jpg)
Pathology Adenocarcinoma: 95%, most
CK20(-), CK7(+)
Squamous cell, small cell, sarcoma, lymphoma
CK20(-), CK7(+)CholangioCa, pancreatic Ca, lung adenoCa
CK20(+), CK7(-)Colon cancer
![Page 31: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/31.jpg)
Growth patternNodular type
Intrahepatic Differential diagnosis of hepatic tumor
HCC, cholangioCa, metastatic tumor
Sclerosing type Hilum and distal Growth along the bile duct, difficult to
diagnosis
![Page 32: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/32.jpg)
Clinical manifestation Painless jaundice
Early in hilum/distal typeLate in intrahepatic type
Abnormal ALP/GGTWeight loss, nausea/vomitPalpable liver
Intrahepatic typeBiliary tract infection
Due to obstruction
![Page 33: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/33.jpg)
Clinical manifestationTumor markers
Elevated serum CEA and CA19-9
![Page 34: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/34.jpg)
Diagnostic evaluation CT scan, ultrasound
For painless jaundice, to exclude stoneERCP (Endoscopic Retrograde
CholangioPancreatography)Biliary tree evaluationIntervention: stenting, brushing cytology
MRI/MRCPNon-invasive entire biliary tree evaluate
![Page 35: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/35.jpg)
Extrahepatic Cholangiocarcinoma
T1 confined to the bile duct
T2 invades beyond the wall of the bile duct
T3 invades the liver, gallbladder, pancreas, and/or unilateral branches of the portal vein or hepatic artery
T4 Invades any of the following: main portal vein or its branches bilaterally, common hepatic artery, or other adjacent structures, such as the colon, stomach, duodenum, or abdominal wall
N1 Regional lymph node metastasis
M1 Distant metastasis
Stage IA T1 N0 M0
Stage IB T2 N0 M0
Stage IIA T3 N0 M0
Stage IIB T1–T3 N1 M0
Stage III T4 Any N M0
Stage IV Any T Any N M1
![Page 36: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/36.jpg)
Intrahepatic CholangiocarcinomaT1 Solitary tumor without vascular invasion
T2 Solitary tumor with vascular invasion or multiple tumors none >5 cm
T3 Multiple tumors >5 cm or tumor involving a major branch of the portal or hepatic veins
T4 Tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum
N1 Nodal metastases to the hepatoduodenal ligament
M1 Any distant metastases
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage IIIA T3 N0 M0
Stage IIIB T4 N0 M0
Stage IIIC Any T N1 M0
Stage IV Any T Any N M1
![Page 37: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/37.jpg)
Treatment Surgery: mainstay
Biliary tree evaluation for resectabilityIntrahepatic: hepatic resectionExtrahepatic: may require
pancreaticoduodenectomy, morbidity
Prognosis: not clear, due to rarity
![Page 38: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/38.jpg)
Multimodality treatment Pre-op neoadjuvant tx
RT, C/T, CRT no benefitPost-op adjuvant tx
RT, C/T, CRT no benefit A trial suggest adjuvant C/T may benefit GB ca Adjuvant CCRT for locally advance dz?
![Page 39: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/39.jpg)
Locally advanced diseaseCCRT, can be considered
5FU/LVGood performanceLiver toxicity, GI toxicity
Palliative chemotherapy
![Page 40: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/40.jpg)
Palliative chemotherapyPooled analysis, extra- and intra-hepatic5FU/LV remained mainstay
Infusion, bolusRR: 20%-30%Survival 6-7m
Combination:Traditional: cisplatin, mitomycinNewer agents: gemcitabine, taxane
![Page 41: Pancreatic Biliary Cancer by Dr Mahipal reddy](https://reader035.vdocuments.us/reader035/viewer/2022062418/554b2d9bb4c905ce088b4ce7/html5/thumbnails/41.jpg)
Palliative procedureBiliary stenting, PTCD
Complication of biliary stentingCommunicate bile duct and intestineBile is sterileResultant repeat infection (BTI)